5XE Stock Chart & Stats
€19.40
€0.40(1.72%)
At close: 4:00 PM EDT
€19.40
€0.40(1.72%)
Day’s Range― - ―
52-Week Range€8.95 - €24.00
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€1.63B
Enterprise Value€3.94B
Total Cash (Recent Filing)€93.47M
Total Debt (Recent Filing)€645.75M
Price to Earnings (P/E)20.3
Beta0.41
Next Earnings
Nov 05, 2026EPS Estimate
0.22Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.32
Shares Outstanding95,046,400
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio1.15
Price to Book (P/B)4.88
Price to Sales (P/S)1.10
P/FCF Ratio28.76
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€24.52Price Target Upside26.40% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)0.94
Revenue Forecast (FY)€1.45B
Bulls Say, Bears Say
Bulls Say
Strong Revenue And EBITDA GrowthThe substantial increase in revenue and adjusted EBITDA shows that Extendicare is expanding through both acquisitions and underlying demand. If this growth continues, greater scale should support investment, strengthen operating leverage, and broaden the company’s position across seniors-care services.
Improved Liquidity And Financing StructureImproved liquidity, longer debt maturities, and a lower average interest rate provide greater financial flexibility for operations, integration, and redevelopment. The unsecured financing structure also reduces near-term refinancing pressure while giving management capacity to execute its growth strategy.
Visible Redevelopment And Home-health GrowthThe combination of targeted home-health volume growth and a visible LTC redevelopment pipeline supports a durable expansion path beyond recent transactions. New capacity and demographic demand can increase service volumes, improve the asset base, and reinforce Extendicare’s long-term market position.
Bears Say
Elevated LeverageThe renewed increase in debt relative to equity leaves Extendicare more exposed to interest costs, operating volatility, and execution setbacks. Although leverage previously improved, the current capital structure remains a constraint on financial flexibility and could limit internally funded growth.
Weak And Volatile Cash ConversionRecent positive cash flow has not consistently matched reported earnings, while the multi-year record includes periods of negative free cash flow. This weak conversion can reduce funding available for debt reduction, dividends, acquisitions, and redevelopment, making execution more dependent on financing.
Home-health Margin And Integration PressureRapid expansion is currently bringing incremental technology and back-office costs that are compressing home-health margins. Ongoing integration spending and the absence of a 2026 Ontario rate increase could delay margin recovery, making the profitability benefits of growth less immediate and less certain.
5XE FAQ
What was Extendicare’s price range in the past 12 months?
Extendicare lowest stock price was €8.95 and its highest was €24.00 in the past 12 months.
What is Extendicare’s market cap?
Extendicare’s market cap is €1.63B.
When is Extendicare’s upcoming earnings report date?
Extendicare’s upcoming earnings report date is Nov 05, 2026 which is in 18 days.
How were Extendicare’s earnings last quarter?
Extendicare released its earnings results on Aug 06, 2026. The company reported €0.201 earnings per share for the quarter, missing the consensus estimate of €0.248 by -€0.048.
Is Extendicare overvalued?
According to Wall Street analysts Extendicare’s price is currently Undervalued.
Does Extendicare pay dividends?
Extendicare does not currently pay dividends.
What is Extendicare’s EPS estimate?
Extendicare’s EPS estimate is 0.22.
How many shares outstanding does Extendicare have?
Extendicare has 95,046,400 shares outstanding.
What happened to Extendicare’s price movement after its last earnings report?
Extendicare reported an EPS of €0.201 in its last earnings report, missing expectations of €0.248. Following the earnings report the stock price went down -4.716%.
Which hedge fund is a major shareholder of Extendicare?
Currently, no hedge funds are holding shares in DE:5XE
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Extendicare Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€24.52 (26.40% Upside)
€24.52 (26.40% Upside)
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
84.96%
12-Months-Change
Fundamentals
Return on Equity
36.33%
Trailing 12-Months
Asset Growth
100.08%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Extendicare
Extendicare Inc. operates across Canada, delivering a wide array of vital care and support services specifically designed for the senior population through its various subsidiaries. The company's diverse service portfolio includes long-term care facilities, a range of retirement living options, and comprehensive home-based health services. These home health offerings span professional nursing care, various rehabilitative therapies (including occupational, physical, and speech therapy), and assistance with everyday activities. Additionally, Extendicare offers contract and consulting expertise to external entities. The organization oversees an extensive network consisting of 119 long-term care residences and retirement communities, alongside its dedicated home health care operations. These services are provided under prominent brand names such as Extendicare, Esprit Lifestyle Communities, ParaMed, Extendicare Assist, and SGP Purchasing Partner Network. Founded in 1968, Extendicare Inc. is headquartered in Markham, Canada.
5XE Stock 12 Month Forecast
Average Price Target
€24.52
▲(26.40% Upside)










